A three-year evaluation of TCu 380Ag and multiload Cu 375 intrauterine devices

Champion, Cheryle B.; Behlilovic, B; J, Arosemena; Randić, Ljiljana; Cole, Lynda Painter; Wilkens, Lynne R.

doi:10.1016/0010-7824(88)90046-7

Cited by 37 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 Pain and bleeding were cause for removal in 5% women in a multinational study conducted in Yugoslavia and Panama . 26 Bhatnagar and colleagues, and Grimes et al reported removal rates ranging from 3.1% to 10.6% on account of pelvic pain.…”

Section: Iucd Removalmentioning

confidence: 97%

A study to evaluate and compare the expulsion and continuation rates of post placental insertion of Cu 375 and CuT 380A in Indian women at a premier hospital in New Delhi, India

Kumar¹,

Kumar

Aggarwal

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: The Study was planned to evaluate and compare the expulsion and continuation rates of post placental insertion of Cu 375 and CuT380A in Indian women at Safdarjung Hospital New Delhi, after approval was obtained from Institutional Ethical committee.Methods: Study group consisted of 300 women, divided into two groups: Group A and Group B. The data was analysed by using ‘student “t” test/ non-parametric ‘Wilcoxon Mann Whitney’ for quantitative variables to evaluate the safety, efficacy and acceptability.Results: Mean age was 24.99 years (range: 19-35years), All women were married (off which 64% literate) and Mean parity in group A was 1.97 and 2.06 in group B. Mean pain score during intrauterine contraceptive device (IUCD) insertion on visual analogue scale was 2.93 in group A and 3 in group B and was not statistically different. 84% women completed 12 months follow up in group A and 83.33% women in group B. Strings were visible in 74% women in group A and in 34% women in group B at 1 month of IUCD insertion. Visibility of strings increased in successive follow up visits and was visible in >80% of women at the end of one year in the both groups. String visibility after intra-Caesarean insertion was delayed. Fifty one percent (n=77) subjects in group A and 54% (n=81) in group B experienced amenorrhea up to six months. Menorrhagia was reported in 7.33% in group A and women 8.66% in group B at the end of 1 year of follow up. Pain was complained by 26 out of 150 (17.3%) women in group A as compared to 36 out of 150 (24%) women in group B after 1 month of insertion. There was no case of PID in group A whereas there were 3 cases of PID in group B. There was no perforation/trauma and pregnancy in either group.Conclusions: Overall expulsion rate was 13% and removal rate was 5% in our study. Continuation rate was 83.3% in Cu 375 and 80.6% in CuT380A at 12 months. There was no significant difference between the IUCDs regarding the safety, efficacy and complications such as expulsion, bleeding etc.

show abstract

Section: Iucd Removalmentioning

confidence: 97%

A study to evaluate and compare the expulsion and continuation rates of post placental insertion of Cu 375 and CuT 380A in Indian women at a premier hospital in New Delhi, India

Kumar¹,

Kumar

Aggarwal

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…In a multinational study ( n = 427) that included the United States and the European countries, 13.8 per 100 women using the Copper T-380A discontinued the IUD over the course of the first year, with 6.9 per 100 women discontinuing because of pain or bleeding 63. In another multinational study ( n = 441) that was conducted in Yugoslavia and Panama, the discontinuation rate was 10 per 100 women, with 5 per 100 women discontinuing because of pain and bleeding 48. Other reasons for IUD discontinuation included infection and a desire for fertility 64.…”

Section: Acceptabilitymentioning

confidence: 99%

Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device

Kaneshiro

Aeby²

2010

IJWH

112

View full text Add to dashboard Cite

The intrauterine device (IUD), primarily in the form of the copper IUD, is used by more than 150 million women around the world, making it the most widely used reversible method of contraception. With a remarkably low failure rate of less than 1 per 100 women in the first year of use, the Copper T-380A is in the top tier of contraceptives in terms of efficacy. Risks of utilization include perforation and an increased risk of infection in the first 20 days following insertion. Overall, the number of adverse events is low, making the Copper T-380A a very safe contraceptive method. The most common reasons for the discontinuation of this method are menstrual bleeding and dysmenorrhea. However, cumulative discontinuation rates of Copper T-380A are lower than that have been reported for other methods, indicating that the Copper T-380A is highly acceptable to women. After 5 years, approximately 50% of all women, who have a Copper T-380A inserted, will continue to use this highly effective contraceptive method.

show abstract

“…Cumulative continuation at 3 years was 49% among LNG-20 users and 59% among TCu380Ag users [8]. Other prospective studies found 3-year continuation rates of 67–78% among users of copper IUDs [9,10]. Continuation of LNG-IUD has been reported at 73–80% at 3 years [11,12].…”

Section: Introductionmentioning

confidence: 99%

Three-year continuation of reversible contraception

Diedrich

Zhao

Madden

et al. 2015

American Journal of Obstetrics and Gynecology

114

View full text Add to dashboard Cite

OBJECTIVE The objective of this analysis was to estimate the 3-year continuation rates of long-acting reversible contraceptive (LARC) methods, and compare these rates to non-LARC methods. STUDY DESIGN The Contraceptive CHOICE Project (CHOICE) was a prospective cohort study that followed 9,256 participants with telephone surveys at 3 and 6 months, then every 6 months for 2–3 years. We estimated 3-year continuation rates of baseline methods chosen for CHOICE including three LARC methods (52mg levonorgestrel intrauterine device, LNG-IUD; the copper intrauterine device, Cu-IUD; and the subdermal implant) and compared these rates to non-LARC hormonal methods (depot medroxyprogesterone acetate, oral contraceptive pills, contraceptive patch, or vaginal ring). Eligibility criteria for this analysis included participants who started their baseline chosen method by the 3-month survey. Participants who discontinued their method to attempt conception were censored. We used a Cox proportional hazard model to adjust for confounding and to estimate the hazard ratio (HR) for risk of discontinuation. RESULTS Our analytic sample consisted of 4,708 CHOICE participants who met inclusion criteria. Three-year continuation rates were 69.8% for users of the LNG-IUD, 69.7% for Cu-IUD users, and 56.2% for implant users. At 3 years, continuation was 67.2% among LARC users and 31.0% among non-LARC users (p <0.001). After adjustment for age, race, education, socioeconomic status, parity, and history of sexually transmitted infection, the hazard ratio for risk of discontinuation was three-fold higher among non-LARC method users than LARC users (HRadj = 3.08, 95% CI 2.80 – 3.39). CONCLUSION Three-year continuation of the two IUDs approached 70%. Continuation of LARC methods was significantly higher than non-LARC methods.

show abstract

A three-year evaluation of TCu 380Ag and multiload Cu 375 intrauterine devices

Cited by 37 publications

References 10 publications

A study to evaluate and compare the expulsion and continuation rates of post placental insertion of Cu 375 and CuT 380A in Indian women at a premier hospital in New Delhi, India

A study to evaluate and compare the expulsion and continuation rates of post placental insertion of Cu 375 and CuT 380A in Indian women at a premier hospital in New Delhi, India

Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device

Three-year continuation of reversible contraception

Contact Info

Product

Resources

About